Pseudomonas aeruginosa

Glenmark Therapeutics Expands Specialty Portfolio with OTIPRIO® Co-Promotion Agreement in the U.S. with Otonomy for Acute Otitis Externa Indication

Retrieved on: 
Thursday, May 2, 2019
Bacteria, Medical specialties, Infectious diseases, RTT, Otitis, Otitis externa, Pediatrics, Glenmark, Pseudomonas aeruginosa, Staphylococcus aureus

Glenmark Therapeutics is dedicated to developing and commercializing a franchise of branded products for Glenmark Pharmaceuticals and is focused in the areas of respiratory and dermatology.

Key Points: 
  • Glenmark Therapeutics is dedicated to developing and commercializing a franchise of branded products for Glenmark Pharmaceuticals and is focused in the areas of respiratory and dermatology.
  • Financial terms for the multi-year agreement were not disclosed; however, Glenmark Therapeutics will provide Otonomy an annual co-promotion fee and provide reimbursement of a proportion of product support expenses.
  • In addition, Otonomy will retain a share of the adjusted gross profits from the sale of OTIPRIO to Glenmark's accounts.
  • The treatment of acute otitis externa in patients 6 months of age and older due to Pseudomonas aeruginosa and Staphylococcus aureus.

Glenmark Therapeutics Expands Specialty Portfolio with OTIPRIO® Co-Promotion Agreement in the U.S. with Otonomy for Acute Otitis Externa Indication

Retrieved on: 
Thursday, May 2, 2019
Bacteria, Medical specialties, Infectious diseases, RTT, Otitis, Otitis externa, Pediatrics, Glenmark, Pseudomonas aeruginosa, Staphylococcus aureus

Glenmark Therapeutics is dedicated to developing and commercializing a franchise of branded products for Glenmark Pharmaceuticals and is focused in the areas of respiratory and dermatology.

Key Points: 
  • Glenmark Therapeutics is dedicated to developing and commercializing a franchise of branded products for Glenmark Pharmaceuticals and is focused in the areas of respiratory and dermatology.
  • Financial terms for the multi-year agreement were not disclosed; however, Glenmark Therapeutics will provide Otonomy an annual co-promotion fee and provide reimbursement of a proportion of product support expenses.
  • In addition, Otonomy will retain a share of the adjusted gross profits from the sale of OTIPRIO to Glenmark's accounts.
  • The treatment of acute otitis externa in patients 6 months of age and older due to Pseudomonas aeruginosa and Staphylococcus aureus.

Forge Receives Second CARB-X Award For Up To $11.1M To Accelerate Development Of Novel Antibiotic To Treat Lung Infections

Retrieved on: 
Thursday, January 3, 2019
Bacteria, Antibiotic-resistant bacteria, Gram-negative bacteria, Pseudomonadales, Pseudomonas aeruginosa, Multiple drug resistance, Antimicrobial resistance, Community for Open Antimicrobial Drug Discovery

This second award will support the development of a new class of LpxC inhibitors to treat serious lung infections attributed to Gram-negative bacteria, including multi-drug resistant P. aeruginosa.

Key Points: 
  • This second award will support the development of a new class of LpxC inhibitors to treat serious lung infections attributed to Gram-negative bacteria, including multi-drug resistant P. aeruginosa.
  • The award commits initial funding up to $5.7M to Forge with the possibility of up to another $5.4M based on the achievement of technical milestones.
  • This second award allows us to evaluate an entirely new class of LpxC inhibitors against drug-resistant superbug infections present in the lung," said Zachary A. Zimmerman, Ph.D., CEO of Forge.
  • "We look forward to advancing our portfolio of novel antibiotics with continued CARB-X support."